Smith & Nephew buying Integra LifeSciences unit

/ / News

Smith & Nephew said it’s buying the extremity orthopedics unit of Integra LifeSciences for $240 million in cash. Smith & Nephew said the deal will provide entry into the shoulder replacement and foot and ankle segment. The business generated revenue of $90 million in 2019 and traded at a small loss, and is expected to be slightly dilutive to trading profit in 2021 and 2022. Integra LifeSciences said the deal will help it focus its portfolio on neurosurgery, surgical instrumentation and regenerative medicine products. Integra will pay $41.5 million to the Consortium of Focused Orthopedists as part of the deal.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.